Lipidic matrix of albendazole: an alternative for systemic infections.

Bollettino chimico farmaceutico

PubMedID: 9859596

Savio E, Domínguez L, Malanga A, Quevedo D, Saldaña J, Camarote C, Ochoa A, Fagiolino P. Lipidic matrix of albendazole: an alternative for systemic infections. Boll Chim Farm. 1998;137(9):345-9.
Albendazole is a poorly water soluble drug, with low oral bioavailability, used in pharmacological treatment of a systemic disease as hydatid parasitosis. Lipidic matrices of Gelucires (44/14 and 35/02) were developed. After "in vitro" studies, one formulation was chosen for a single dose study in 8 healthy volunteers, with a cross-over and randomised design, taking a commercially available tablet as reference. Drug absorption was followed by albendazole sulphoxide dosage in urine by high pressure liquid chromatography. Neither albendazole nor albendazole sulphoxide were recovered in urine after tablet administration while 0.18% (+/- 0.06) of dose was recovered after lipidic matrix administration in the first 24 hours. Besides ageing control were performed up to 18 months post-elaboration. Lipidic matrix with Gelucire 44/14 was revealed as a promising attempt for oral pharmaceutical form in albendazole systemic treatment.